The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Genetics and drug discovery had its origins in the 1980s with the development of positional cloning technology—that is, using genetic markers to map and identify the genes responsible for Mendelian ...

Targeted rewriting of the epigenome promises to overcome several challenges in direct gene editing in patient therapies.

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

CRISPR gene editing shows potential for treating genetic diseases. Explore how it may impact Down syndrome treatment and ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

While Rosie O’Donnell, 63, made a name for herself as a Broadway star and host of the Emmy-winning talk show The Rosie ...

AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. AstraZeneca PLC (NASDAQ:AZN) is ...

Q2 2025 Earnings Call Transcript July 29, 2025 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.13, ...

WASHINGTON (Reuters) -AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by ...

AstraZeneca's strategic $50B investment promises to revolutionize U.S. medicine production with advanced manufacturing and ...

AstraZeneca has announced a US$50 billion investment in the United States by 2030, building on America’s global leadership in ...